

**500****Technology Fast 500**
2016 APAC
Deloitte.

**GNI Group Ltd. Ranks 119th in the 15th Deloitte Touche Tohmatsu Limited
Asia Pacific Technology Fast 500,
A Ranking Program of Fastest-Growing Technology Companies**

December, 6 2016 - GNI Group Ltd., (TSE Mothers listed code: 2160) a leading biopharmaceutical company listed in Japan, announced today that it ranked 119th in the 15th Asia Pacific Technology Fast 500 with revenue growth of 454% based on past three according periods. Asia Pacific Technology Fast 500, announced annually by Deloitte Touche Tohmatsu Limited (DTTL), is a ranking of the 500 fastest-growing companies in the technology, media, and telecommunications (TMT) industries based on their revenue (sales) growth percentage based on the last three accounting periods. Please visit www.deloitte.com/fast500asiapacific

The DTTL Technology Fast 500 is the pre-eminent technology awards program in Asia Pacific, and now in its 15th year, its includes eight Asia Pacific locations: Australia; China (including Hong Kong); India; Japan; South Korea; New Zealand; Singapore and Taiwan. Combining technological innovation, entrepreneurship and rapid growth, Technology Fast 500 companies are large, small, public and private, and span a variety of industry sectors including hardware, software, telecommunications, Media, life sciences and clean technology.

For further information on Asia Pacific Technology Fast 500, please visit <https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Technology-Media-Telecommunications/gx-tech-fast-500-apac-ranking-report-2016.pdf>

About GNI Group Ltd.

GNI Group Ltd. is a multinational biopharmaceutical company focused on research, development, manufacture, and commercialization of therapeutic agents for endemic diseases in Asia and worldwide. In addition to its CFDA Class 1.1 approved drug Etuary®, the only approved therapy for Idiopathic Pulmonary Fibrosis in China, GNI Group Ltd. has a robust drug development pipeline focused on innovative therapeutic agents for diseases including radiation pneumonitis, diabetic nephropathy, liver fibrosis (cirrhosis), acute-on-chronic liver failure (ACLF) and acute promyelocytic leukemia (APL). GNI Group Ltd. is listed on the Tokyo Stock Exchange Mothers Market, Code 2160, with headquarters in Tokyo and subsidiaries in Hong Kong, Shanghai, Beijing and the United States. For further information, please visit www.gnipharma.com.

For further inquiries

+81 (03) -6214-3600

Email: infojapan@gnipharma.com

This press release contains "forward-looking" statements, including statements related to our group's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to", "will" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause our group's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. Our group does not undertake any obligation to update forward-looking statements.